Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2026
Reporting Period: This filing serves as a disclosure of forward-looking guidance for the full year 2026. It does not report historical financial results for a specific past period.
Key Financial Metrics
This Form 8-K does not contain historical financial statements, revenue, profit, cash flow, margins, debt, or liquidity figures. The filing solely references the issuance of a press release and investor presentation containing full-year 2026 revenue and adjusted EBITDA guidance. Specific numerical values for these metrics are not provided in the text of this filing; they are contained in the attached exhibits (Exhibit 99.1 and 99.2).
Material Changes
No material changes to historical financial performance are reported in this document. The filing announces the release of new forward-looking financial guidance for the upcoming fiscal year.
Guidance, Outlook, and Risks
Management Commentary and Guidance
On January 8, 2026, the Company issued a press release and corporate presentation providing full-year 2026 guidance, specifically covering:
- Projected product revenue.
- Adjusted operating expenses.
- Adjusted EBITDA.
Management notes that these figures reflect current beliefs and expectations regarding market opportunities and assumptions.
Risks and Contingencies
The filing includes extensive safe harbor language regarding forward-looking statements. Key risks that could cause actual results to differ materially from guidance include:
- Uncertainty of expected financial performance and market acceptance of products.
- Ability to commercialize products and manage relationships with licensors.
- Competition from other products and regulatory approval maintenance.
- Reimbursement and third-party payor contract outcomes.
- Supply chain constraints for active pharmaceutical ingredients and manufacturing.
- Patent infringement litigation and governmental investigations.
- Customer concentration and the need for additional financing.
Investor Verification Checklist
- Review Exhibit 99.1: Verify the specific numerical targets for 2026 revenue and adjusted EBITDA in the attached press release.
- Review Exhibit 99.2: Examine the investor presentation for detailed assumptions regarding market size and expense projections.
- Assess Risk Factors: Cross-reference the risks listed in this 8-K with the "Risk Factors" section of the most recent Form 10-K or 10-Q.
- Confirm Liquidity Needs: Given the mention of the "ability to obtain funding," verify the Company's current cash position and burn rate in recent quarterly filings.